Suitable for

18 years of age or above

Effective prevention

Recombinant influenza vaccine (RIV) contains haemagglutinin (a surface protein of influenza virus) that is produced by recombinant technology, and does not require egg or influenza virus in the production process.

Inoculation time

     18 years of age or above : 1 dose

Common side effects

     Mild side effects generally only last for 1-2 days
     Slight redness, swelling and pain at the injection site, limited arm movement

Not suitable for

     People with high fever and severe physical discomfort should not be vaccinated, and can only be vaccinated after recovery

     Those with bleeding disorders or on anticoagulants should consult their doctors for advice.

  Vaccine Name

VAXNEUVANCE™

  Pharmaceutical factory

  Number of serotypes

  Number of inoculations

People over 18 years old only need 1 dose (intramuscular injection)

  Features

        The 15-valent pneumococcal vaccine is effective against serotype 3 pneumococcus, has a stronger immune response.
        Prevent invasive pneumococcal infections such as pneumonia, acute otitis media, meningitis, sepsis, and others.
        It has been approved for use by the US FDA and the European Union, as well as in the United Kingdom, the United States, Australia, and Canada.

  Side Effects

        Pain, swelling, redness at the injection site
        Fatigue
        Muscle pain
        Headache
        Joint pain
  ** Side effects are mild and only last for a short period of time.

  Suitable for

        4 injections are recommended for babies from 6 weeks to 11 months        
        Only one injection for 2 years old or older

  Not suitable for

        People who have had severe allergic responses to any component of the vaccination (including antigens and protein carriers).
        People who have had severe allergic reactions to diphtheria vaccine components.

  Precautions

        Can be given inactivated influenza vaccination at the same time.
        High-risk groups, such as the elderly, long-term patients, those who have had invasive pneumococcal illness, those with reduced immunity, and those with neurological problems, should be vaccinated with the 15-valent pneumococcal vaccine.